Advanced or metastatic untreated EGFR mutation positive NSCLC
Conditions
Brief summary
OS in patients treated with osimertinib first or dacomitinib first
Detailed description
• OS in patients treated with osimertinib first followed by dacomitinib and in patients treated with dacomitinib first followed by osimertinib • PFS at the time of study second-line therapy failure (PFS2) in patients treated with front-line osimertinib or dacomitinib; • PFS in patients treated with osimertinib first or dacomitinib first; • Response Rate (RR) with dacomitinib or osimertinib; • RR, PFS and OS with osimertinib followed by dacomitinib or with the opposite sequence in patients with u
Interventions
DRUGTAGRISSO 80 mg film-coated tablets
Sponsors
Fondazione Ricerca Traslazionale
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS in patients treated with osimertinib first or dacomitinib first | — |
Secondary
| Measure | Time frame |
|---|---|
| • OS in patients treated with osimertinib first followed by dacomitinib and in patients treated with dacomitinib first followed by osimertinib • PFS at the time of study second-line therapy failure (PFS2) in patients treated with front-line osimertinib or dacomitinib; • PFS in patients treated with osimertinib first or dacomitinib first; • Response Rate (RR) with dacomitinib or osimertinib; • RR, PFS and OS with osimertinib followed by dacomitinib or with the opposite sequence in patients with u | — |
Countries
Italy, Spain
Outcome results
None listed